These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7556150)

  • 61. Recombinant factor VIII SQ--the influence of formulation parameters on structure and surface adsorption.
    Fatouros A; Sjöström B
    Int J Pharm; 2000 Jan; 194(1):69-79. PubMed ID: 10601686
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The functional domains of coagulation factor VIII:C.
    Burke RL; Pachl C; Quiroga M; Rosenberg S; Haigwood N; Nordfang O; Ezban M
    J Biol Chem; 1986 Sep; 261(27):12574-8. PubMed ID: 3017981
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion.
    Doering CB; Healey JF; Parker ET; Barrow RT; Lollar P
    J Biol Chem; 2004 Feb; 279(8):6546-52. PubMed ID: 14660593
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.
    Besman MJ; Shiba D
    Pharm Res; 1997 Aug; 14(8):1092-8. PubMed ID: 9279894
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recombinant porcine prorelaxin produced in Chinese hamster ovary cells is biologically active.
    Vu AL; Green CB; Roby KF; Soares MJ; Fei DT; Chen AB; Kwok SC
    Life Sci; 1993; 52(12):1055-61. PubMed ID: 8445994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer.
    Hoeben RC; van der Jagt RC; Schoute F; van Tilburg NH; Verbeet MP; Briët E; van Ormondt H; van der Eb AJ
    J Biol Chem; 1990 May; 265(13):7318-23. PubMed ID: 2110164
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells.
    Israel DI; Nove J; Kerns KM; Moutsatsos IK; Kaufman RJ
    Growth Factors; 1992; 7(2):139-50. PubMed ID: 1419071
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intersubunit fluorescence energy transfer in human factor VIII.
    Fay PJ; Smudzin TM
    J Biol Chem; 1989 Aug; 264(24):14005-10. PubMed ID: 2503509
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The manufacturing process of recombinant factor VIII, recombinate.
    Gomperts E; Lundblad R; Adamson R
    Transfus Med Rev; 1992 Oct; 6(4):247-51. PubMed ID: 1421823
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Viral safety of B-domain deleted recombinant factor VIII.
    Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
    Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Protein and cDNA sequence of a glycine-rich, dimethylarginine-containing region located near the carboxyl-terminal end of nucleolin (C23 and 100 kDa).
    Lapeyre B; Amalric F; Ghaffari SH; Rao SV; Dumbar TS; Olson MO
    J Biol Chem; 1986 Jul; 261(20):9167-73. PubMed ID: 3755137
    [TBL] [Abstract][Full Text] [Related]  

  • 72. No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products.
    Astermark J; Ekman M; Berntorp E
    Br J Haematol; 1997 Nov; 99(2):289-94. PubMed ID: 9375741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant factor VIII SQ--inactivation kinetics in aqueous solution and the influence of disaccharides and sugar alcohols.
    Fatouros A; Osterberg T; Mikaelsson M
    Pharm Res; 1997 Dec; 14(12):1679-84. PubMed ID: 9453053
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Site-directed mutagenesis and expression of coagulation factors VIII and V in mammalian cells.
    Pittman DD; Kaufman RJ
    Methods Enzymol; 1993; 222():236-60. PubMed ID: 8412797
    [No Abstract]   [Full Text] [Related]  

  • 75. The manufacturing of the recombinant factor VIII, Kogenate.
    Boedeker BG
    Transfus Med Rev; 1992 Oct; 6(4):256-60. PubMed ID: 1421825
    [No Abstract]   [Full Text] [Related]  

  • 76. Monitoring cellular state transitions in a production-scale CHO-cell process using an electronic nose.
    Bachinger T; Riese U; Eriksson R; Mandenius CF
    J Biotechnol; 2000 Jan; 76(1):61-71. PubMed ID: 10784297
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exploration of structure-function relationships in human factor VIII by site-directed mutagenesis.
    Toole JJ; Pittman D; Murtha P; Wasley LC; Wang J; Amphlett G; Hewick R; Foster WB; Kamen R; Kaufman RJ
    Cold Spring Harb Symp Quant Biol; 1986; 51 Pt 1():543-9. PubMed ID: 3034488
    [No Abstract]   [Full Text] [Related]  

  • 78. Expression and structure-function properties of recombinant factor VIII.
    Kaufman RJ
    Transfus Med Rev; 1992 Oct; 6(4):235-46. PubMed ID: 1421822
    [No Abstract]   [Full Text] [Related]  

  • 79. Recombinate: viral safety and final product manufacturing testing and specifications.
    Lawrence J
    Ann Hematol; 1994; 68 Suppl 3():S21-4. PubMed ID: 8180253
    [No Abstract]   [Full Text] [Related]  

  • 80. Cell culture and purification process--purity and safety testing.
    Koplove HM
    Ann Hematol; 1994; 68 Suppl 3(Suppl 3):S15-20. PubMed ID: 8180252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.